The immunologic basis for the treatment of psoriasis with new biologic agents
Top Cited Papers
- 1 January 2002
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 46 (1) , 1-26
- https://doi.org/10.1067/mjd.2002.120568
Abstract
No abstract availableKeywords
This publication has 129 references indexed in Scilit:
- The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyJournal of the American Academy of Dermatology, 2001
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- Inflammatory Skin Diseases, T Cells, and Immune SurveillanceNew England Journal of Medicine, 1999
- The expanding universe of T-cell subsets: Th1, Th2 and morePublished by Elsevier ,1999
- Molecular Mechanisms of Lymphocyte Homing to Peripheral Lymph NodesThe Journal of Experimental Medicine, 1998
- Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?Immunology Today, 1995
- An approach to the treatment of moderate to severe psoriasis with rotational therapyJournal of the American Academy of Dermatology, 1993
- Remission of psoriatic lesions with muromonab-CD3 (Orthoclone OKT3) treatmentJournal of the American Academy of Dermatology, 1989
- T lymphocytes and monocytes bind to keratinocytes in frozen sections of biopsy specimens of normal skin treated with gamma interferonJournal of the American Academy of Dermatology, 1989
- Psoriasis: a disease of abnormal Keratinocyte proliferation induced by T lymphocytesImmunology Today, 1986